SCHEMBL277449

SCHEMBL277449

Oc1cccc2ccnnc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.57
TSHR P16473 2/20 0.57
MMP2 P08253 1/20 0.57
CHRM1 P11229 1/20 0.57
COMT P21964 1/20 0.57
ADRA1A P35348 1/20 0.57
METAP1 P53582 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
KDM4E B2RXH2 9/20 0.48
ALOX12 P18054 4/20 0.48
PLAU P00749 1/20 0.48
NCF1 P14598 1/20 0.48
ALDH1A1 P00352 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47
HIF1A Q16665 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3074924 0.77 TSHR (0.42) METAP2TSHRMMP2CHRM1COMT
SCHEMBL2008753 0.74 KDM4E (0.39) METAP2TSHRMMP2CHRM1COMT
SCHEMBL3886362 0.74 MMP2 (0.34) METAP2TSHRMMP2CHRM1COMT
SCHEMBL10841983 0.74 MEN1 (0.39) METAP2TSHRMMP2CHRM1COMT
SCHEMBL19001485 0.74 MMP2 (0.34) METAP2TSHRMMP2CHRM1COMT
SCHEMBL1765856 0.74 CYP3A4 (0.39) METAP2TSHRMMP2CHRM1COMT
SCHEMBL12737722 0.74 BACE1 (0.48) METAP2TSHRMMP2CHRM1COMT
SCHEMBL19055257 0.74 PSMD14 (0.57) METAP2TSHRMMP2CHRM1COMT
SCHEMBL3887261 0.74 LMNA (0.38) METAP2TSHRMMP2ADRA1AKDM4E
SCHEMBL277448 0.74 KDM4E (0.34) METAP2TSHRMMP2CHRM1COMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2493956-B1 MOISTURE-CURING FORMULATIONS WITH TIME-MODIFIED CURING BEHAVIOR HENKEL AG & CO KGAA (DE) 2018-04-18 EP claimed
US-9428529-B2 Process for purification of trivalent phosphorous ligands that can be used for preparation of catalysts DOW TECHNOLOGY INVESTMENTS LLC (US) 2016-08-30 US claimed
CN-102712751-B Moisture-curing formulations with time-modified phases HENKEL AG & CO KGAA 2015-06-10 CN claimed
US-8592517-B2 Moisture-curing formulations with time-modified phases HENKEL AG & CO. KGAA (DE) 2013-11-26 US claimed
US-20120277373-A1 MOISTURE-CURING FORMULATIONS WITH TIME-MODIFIED PHASES HENKEL AG & CO. KGAA (DE) 2012-11-01 US claimed
EP-1558585-A4 NEUROLOGICALLY-ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LTD (AU) 2008-07-02 EP claimed
CN-1720238-A Neurologically-active compounds PRANA BIOTECHNOLOGY LTD (AU) 2006-01-11 CN claimed
EP-1558585-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS Prana Biotechnology Ltd (AU) 2005-08-03 EP claimed
WO-2004031161-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2004-04-15 WO claimed
US-5385990-A Blend of epoxy compound, amine hardener and hydroxy substituted aromatic compound LORD CORPORATION (US) 1995-01-31 US claimed
EP-0596622-A2 Epoxy resin structural adhesive composition having high temperature resistance LORD CORPORATION (US) 1994-05-11 EP claimed
EP-0377357-B1 Process for the condensation of at least one epoxide on at least one cyclic anhyhride in the presence of a titanium-based catalyst INST FRANCAIS DU PETROLE (FR) 1994-03-23 EP claimed
US-20200339598-A1 POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2020-10-29 US disclosed
CN-106009788-B Coating liquid for forming coating film, method for producing same, and method for producing substrate with coating film 日挥触媒化成株式会社 2020-06-16 CN disclosed
CN-106497400-B Coating liquid for forming coating film, method for producing coating liquid for forming coating film, and substrate with coating film 日挥触媒化成株式会社 2020-04-03 CN disclosed
EP-2607416-B1 THERMOPLASTIC RESIN FOAM, METHOD OF PRODUCING THE SAME, AND LIGHT REFLECTING MATERIAL USING THE SAME FURUKAWA ELECTRIC CO LTD (JP) 2019-10-02 EP disclosed
EP-0671397-A1 Alkylaminoindanes compounds, processes for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1995-09-13 EP disclosed
US-5385990-A Blend of epoxy compound, amine hardener and hydroxy substituted aromatic compound LORD CORPORATION (US) 1995-01-31 US disclosed
EP-0596622-A2 Epoxy resin structural adhesive composition having high temperature resistance LORD CORPORATION (US) 1994-05-11 EP disclosed
US-4143075-A RHODIUM-CARBON MONOXIDE-TRIARYLPHOSPHINE CATALYST, SEQUESTERING IRON SALT CONTAMINANTS UNION CARBIDE CORPORATION (US) 1979-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339598-A1 POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY NR4A1, NCOA4, NR4A2 METAP2 3811/4885TSHR 2821/4885MMP2 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.